Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624541 | 0.88 | OGA (0.37) | OGACHRNB2CHRNA4KMT2ACHRNB4 | |
| SCHEMBL6626343 | 0.85 | OGA (0.38) | OGACHRNB2CHRNA4KMT2AHTR3A | |
| SCHEMBL3566046 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNA4KMT2ACHRNA7HTR3A | |
| SCHEMBL3574996 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4KMT2ACHRNB4CHRNA3 | |
| SCHEMBL1449402 | 0.77 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1023396 | 0.74 | CHRNB2 (0.37) | CHRNB2CHRNA4KMT2ACHRNA7HTR3A | |
| SCHEMBL3564137 | 0.74 | HTR1A (0.34) | HRH3 | |
| SCHEMBL2676639 | 0.74 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL20255468 | 0.73 | HRH3 (0.49) | OGAHRH3 | |
| SCHEMBL1449966 | 0.73 | CHRNA7 (0.43) | CHRNA7HTR3ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910578-B2 | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-2029607-A1 | NOVEL 8,10-DIAZA-BICYCLOÝ4.3.1¨DECANE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135121-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | CHRNA10, CHRNA7, CHRNA3 | OGA 1608/4885CHRNB2 8/4885CHRNA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.